TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.

Oliver Dorigo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.